Genprex Inc (GNPX)

$3.00 -0.30 (-9.09%)
Market Cap 8.97M
Revenue (ttm) 0.00
Net Income (ttm) -21.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,722,900
Avg Vol 587,508
Day's Range N/A - N/A
Shares Out 3.12M
Stochastic %K 86%
Beta -0.81
Analysts Strong Buy
Price Target $375.00

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 774 4679
Address:
3300 Bee Cave Road, Suite 650-227, Austin, United States
ace6th
ace6th Jan. 17 at 12:14 AM
$GCTK ------> $GNPX Superior to this
0 · Reply
Diamond_Playz
Diamond_Playz Jan. 16 at 10:14 PM
He called it early before anyone else. Love adding before the runs✅ @ReversalFox is one of the best follows out there. I’ve banked on his calls recently 💎 Got more $ARBK $NVNI - $GNPX $QS -
0 · Reply
Stockman189
Stockman189 Jan. 16 at 9:41 PM
$GNPX these trolls are like old, bitter ex-girlfriends…mad AF at the stock! 😂
2 · Reply
SEC_LIARS
SEC_LIARS Jan. 16 at 9:41 PM
$GNPX One of the most common things I’ve seen with scam stocks is people saying the price dropped on low volume. Low volume? It was trading at one eighth of its normal volume. Seriously?
0 · Reply
MB76
MB76 Jan. 16 at 9:24 PM
$GNPX Thinking about buying this stock? Try rolling down your window and throwing out the money, it’s more enjoyable with the same effect!!!
1 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 16 at 8:53 PM
$GNPX A pullback on low volume is 👌 for next week !!
0 · Reply
POSGNPX
POSGNPX Jan. 16 at 8:34 PM
$GNPX bear trap is closing.
0 · Reply
SEC_LIARS
SEC_LIARS Jan. 16 at 8:12 PM
$GNPX MC is 6M with 75M ATM. lol.
1 · Reply
shuffle13
shuffle13 Jan. 16 at 6:22 PM
$GNPX what was our drop attributed today?
2 · Reply
byers07
byers07 Jan. 16 at 5:58 PM
$GNPX got 2 hundred more shares with JFBR profits here at 3
0 · Reply
Latest News on GNPX
Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Jan 7, 2026, 7:00 AM EST - 9 days ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Jan 6, 2026, 7:00 AM EST - 10 days ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 24, 2025, 7:00 AM EST - 7 weeks ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 19, 2025, 7:00 AM EST - 2 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 18, 2025, 7:00 AM EST - 2 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Nov 4, 2025, 7:00 AM EST - 2 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 11:19 AM EDT - 2 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 28, 2025, 7:00 AM EDT - 2 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 8:12 AM EDT - 3 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 7:00 AM EDT - 3 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Sep 2, 2025, 8:30 AM EDT - 4 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 18, 2025, 9:29 AM EDT - 5 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Aug 4, 2025, 8:30 AM EDT - 5 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 24, 2025, 9:25 AM EDT - 7 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 7 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO 2025 International Convention

Jun 3, 2025, 7:00 AM EDT - 8 months ago

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025, 7:00 AM EDT - 8 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025, 7:00 AM EDT - 8 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025, 7:00 AM EDT - 9 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025, 7:00 AM EDT - 9 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 30, 2025, 7:30 AM EDT - 9 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 9 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 28, 2025, 7:30 AM EDT - 9 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 24, 2025, 8:15 AM EDT - 9 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Apr 22, 2025, 8:15 AM EDT - 9 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 26, 2025, 8:15 AM EDT - 10 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 25, 2025, 8:15 AM EDT - 10 months ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO Europe Spring 2025

Mar 4, 2025, 8:15 AM EST - 11 months ago

Genprex to Participate at BIO Europe Spring 2025

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 19, 2025, 8:15 AM EST - 11 months ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 18, 2025, 8:15 AM EST - 11 months ago

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex to Participate in 2024 BIO Europe Conference

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Aug 14, 2024, 9:25 AM EDT - 1 year ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Aug 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Genprex to Present at the August Sidoti Microcap Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Genprex to Present at the August Sidoti Microcap Conference

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Jun 27, 2024, 8:31 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

ace6th
ace6th Jan. 17 at 12:14 AM
$GCTK ------> $GNPX Superior to this
0 · Reply
Diamond_Playz
Diamond_Playz Jan. 16 at 10:14 PM
He called it early before anyone else. Love adding before the runs✅ @ReversalFox is one of the best follows out there. I’ve banked on his calls recently 💎 Got more $ARBK $NVNI - $GNPX $QS -
0 · Reply
Stockman189
Stockman189 Jan. 16 at 9:41 PM
$GNPX these trolls are like old, bitter ex-girlfriends…mad AF at the stock! 😂
2 · Reply
SEC_LIARS
SEC_LIARS Jan. 16 at 9:41 PM
$GNPX One of the most common things I’ve seen with scam stocks is people saying the price dropped on low volume. Low volume? It was trading at one eighth of its normal volume. Seriously?
0 · Reply
MB76
MB76 Jan. 16 at 9:24 PM
$GNPX Thinking about buying this stock? Try rolling down your window and throwing out the money, it’s more enjoyable with the same effect!!!
1 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 16 at 8:53 PM
$GNPX A pullback on low volume is 👌 for next week !!
0 · Reply
POSGNPX
POSGNPX Jan. 16 at 8:34 PM
$GNPX bear trap is closing.
0 · Reply
SEC_LIARS
SEC_LIARS Jan. 16 at 8:12 PM
$GNPX MC is 6M with 75M ATM. lol.
1 · Reply
shuffle13
shuffle13 Jan. 16 at 6:22 PM
$GNPX what was our drop attributed today?
2 · Reply
byers07
byers07 Jan. 16 at 5:58 PM
$GNPX got 2 hundred more shares with JFBR profits here at 3
0 · Reply
_ClockyTrends
_ClockyTrends Jan. 16 at 4:57 PM
Picked up on @metricwhale Alert it was🔥 If you trade he’s someone you should follow. $SLB $MMM $DXF $GNPX Xxvz
0 · Reply
Javivi33
Javivi33 Jan. 16 at 4:54 PM
$GNPX again, all the gamblers out. Invest money you are williing to lose or stay out of this game.
1 · Reply
DagZahav
DagZahav Jan. 16 at 4:41 PM
$GNPX Just to remind people how volatile this stock can be in late October it went from $0.25 to 0.72 (pre split) in 2 days got much higher but I got out at .72
0 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 16 at 4:36 PM
$GNPX This is very constructive price action as it pulls back on lighter volume. Look at the volume on green days, thats serious accumulation (Institutions).
0 · Reply
Stockman189
Stockman189 Jan. 16 at 4:17 PM
$GNPX she’s a beaut Clark!
0 · Reply
byers07
byers07 Jan. 16 at 4:12 PM
$GNPX Stay here I’ll bring my JFBR profits before EOD
0 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 16 at 4:07 PM
$GNPX green close ?
0 · Reply
www_larval_com
www_larval_com Jan. 16 at 3:52 PM
Dumbo reporting in! $GNPX just reversed 4% higher to -9% (~953Kv) a few minutes ago, follow for more volatility.
0 · Reply
William_H_Bonney
William_H_Bonney Jan. 16 at 3:33 PM
$GNPX lol it just went from 1,7 to 3,5. Bad with math?
1 · Reply
SEC_LIARS
SEC_LIARS Jan. 16 at 3:27 PM
$GNPX If you truly believe this scam stock will go up, then go ahead and buy it. Just do not do something foolish like buying it at prices above $2.
0 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 16 at 3:17 PM
$GNPX buying opportunity imho crazy accumulation lately.
2 · Reply
Longhorns88
Longhorns88 Jan. 16 at 3:16 PM
$GNPX Also, don’t let the idiots on this page scare you. Bullish call options flow, accumulation levels are HUGE past few days, and congressman Tim Moore has averages at $7, $5, and $2.50. Next week we’re at $5.00
1 · Reply